百济神州(06160)下跌5.04%，报85.8元/股

金融界06-27

6月27日，百济神州(06160)盘中下跌5.04%，截至13:28，报85.8元/股，成交5076.32万元。

百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。

截至2024年一季报，百济神州营业总收入53.33亿元、净利润-17.82亿元。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446377075?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-27 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446377075","market":"hk","top_or_hot":-1,"title":"百济神州(06160)下跌5.04%，报85.8元/股","media":"金融界","content":"<html><body><div>\n<p>6月27日，<span><a href=\"https://laohu8.com/S/688235\">百济神州</a></span>(06160)盘中下跌5.04%，截至13:28，报85.8元/股，成交5076.32万元。</p><p><a href=\"https://laohu8.com/S/06160\">百济神州</a>有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。</p><p>截至2024年一季报，百济神州营业总收入53.33亿元、净利润-17.82亿元。</p>\n<div>\n<div>\n</div>\n</div>\n</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州(06160)下跌5.04%，报85.8元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州(06160)下跌5.04%，报85.8元/股\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">金融界</strong><span class=\"h-time small\">2024-06-27 13:28</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>6月27日，<span><a href=\"https://laohu8.com/S/688235\">百济神州</a></span>(06160)盘中下跌5.04%，截至13:28，报85.8元/股，成交5076.32万元。</p><p><a href=\"https://laohu8.com/S/06160\">百济神州</a>有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。</p><p>截至2024年一季报，百济神州营业总收入53.33亿元、净利润-17.82亿元。</p>\n<div>\n<div>\n</div>\n</div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://hk.jrj.com.cn/2024/06/27132841231327.shtml\">金融界</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://hk.jrj.com.cn/2024/06/27132841231327.shtml","article_id":"2446377075","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446377075","pubTimestamp":1719466083,"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"6月27日，百济神州(06160)盘中下跌5.04%，截至13:28，报85.8元/股，成交5076.32万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2024年一季报，百济神州营业总收入53.33亿元、净利润-17.82亿元。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","06160":"百济神州","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1500":"做空集合股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK1583":"高瓴概念","BK1588":"回港中概股","BK4535":"淡马锡持仓","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4588":"碎股","BK4526":"热门中概股","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK0239":"医药制造","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","BK4505":"高瓴资本持仓","BGNE":"百济神州"},"translate_title":"BeiGene (06160) fell 5.04% to 85.8 yuan per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"BGNE":1,"06160":1},"content_text":"6月27日，百济神州(06160)盘中下跌5.04%，截至13:28，报85.8元/股，成交5076.32万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2024年一季报，百济神州营业总收入53.33亿元、净利润-17.82亿元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446377075"}